SIRT3 and metabolic dysfunction-associated steatotic liver disease: The Sirt3/FOXO3a pathway was reported to promote autophagy in liraglutide-treated mice with non-alcoholic fatty liver disease (Tong et al., 2016) and in a rat model of exsanguinating cardiac arrest treated by emergency preservation and resuscitation (Ma et al., 2019).